CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(02): 148-159
DOI: 10.1055/a-0818-5440
GebFra Science
Guideline/Leitlinie
Georg Thieme Verlag KG Stuttgart · New York

Prevention of Cervical Cancer. Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) – Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia

Article in several languages: English | deutsch
Peter Hillemanns
1   Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover, Hannover, Germany
,
Klaus Friese
2   Klinik Bad Trissl GmbH, Oberaudorf, Germany
,
Christian Dannecker
3   Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Germany
,
Stefanie Klug
4   Lehrstuhl für Epidemiologie, Technische Universität München, München, Germany
,
Ulrike Seifert
5   Tumorepidemiologie, Universitäts KrebsCentrum (UCC), Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany
,
Thomas Iftner
6   Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, Universitätsklinikum Tübingen, Tübingen, Germany
,
Juliane Hädicke
6   Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, Universitätsklinikum Tübingen, Tübingen, Germany
,
Thomas Löning
7   Institut für Pathologie, Albertinen-Krankenhaus Hamburg, Hamburg, Germany
,
Lars Horn
8   Institut für Pathologie, Universitätsklinikum Leipzig, Leipzig, Germany
,
Dietmar Schmidt
9   Institut für Pathologie, Referenzzentrum für Gynäkopathologie, Mannheim, Germany
,
Hans Ikenberg
10   CytoMol – MVZ für Zytologie und Molekularbiologie, Frankfurt, Germany
,
Manfred Steiner
11   Facharzt für Frauenheilkunde und Geburtshilfe, Ihringen, Germany
,
Ulrich Freitag
12   Facharzt für Frauenheilkunde und Geburtshilfe, Wismar, Germany
,
Uwe Siebert
13   Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria
14   Division of Health Technology Assessment and Bioinformatics, ONCOTYROL – Center for Personalized Cancer Medicine, Innsbruck, Austria
,
Gaby Sroczynski
13   Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria
,
Willi Sauerbrei
15   Institut für Med. Biometrie und Statistik (IMBI), Universitätsklinikum Freiburg, Freiburg, Germany
,
Matthias W. Beckmann
16   Frauenklinik, Universitätsklinikum Erlangen, Erlangen, Germany
,
Marion Gebhardt
17   Frauenselbsthilfe nach Krebs, Forchheim, Germany
,
Michael Friedrich
18   Klinik für Frauenheilkunde und Geburtshilfe, Helios Klinikum Krefeld, Krefeld, Germany
,
Karsten Münstedt
19   Frauenklinik, Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany
,
Achim Schneider
20   Medizinisches Versorgungszentrum im Fürstenberg-Karree, Berlin, Germany
,
Andreas Kaufmann
21   Klinik für Gynäkologie, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Berlin, Germany
,
K. Ulrich Petry
22   Frauenklinik, Klinikum Wolfsburg, Wolfsburg, Germany
,
Axel P. A. Schäfer
23   Facharzt für Frauenheilkunde und Geburtshilfe, Berlin, Germany
,
Michael Pawlita
24   Deutsches Krebsforschungszentrum, Heidelberg, Germany
,
Joachim Weis
25   Klinik für Tumorbiologie, Klinik für Onkologische Rehabilitation – UKF Reha gGmbH, Freiburg, Germany
,
Anja Mehnert
26   Abteilung für Medizinische Psychologie und Medizinische Soziologie, Universitätsklinikum Leipzig, Leipzig, Germany
,
Mathias Fehr
27   Gynäkologie & Geburtshilfe in Frauenfeld, Spital Thurgau AG, Frauenfeld, Switzerland
,
Christoph Grimm
28   Privatklinik Döbling, Wien, Austria
,
Olaf Reich
29   Privatklinik Graz Ragnitz, Graz, Austria
,
Marc Arbyn
30   Cancer Center, Sciensano, Brüssel, Belgium
,
Jos Kleijnen
31   Kleijnen Systematic Reviews Ltd, York, United Kingdom
,
Simone Wesselmann
32   Deutsche Krebsgesellschaft, Berlin, Germany
,
Monika Nothacker
33   AWMF-Institut für Medizinisches Wissensmanagement, Marburg, Germany
,
Markus Follmann
34   Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Berlin, Germany
,
Thomas Langer
34   Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Berlin, Germany
,
Matthias Jentschke
1   Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover, Hannover, Germany
› Author Affiliations
Further Information

Publication History

received 21 August 2018
revised 03 December 2018

accepted 08 December 2018

Publication Date:
18 February 2019 (online)

Abstract

Aims Annual opportunistic screening for cervical carcinoma has been carried out in Germany since 1971. The creation of this S3 guideline meets an important need, outlined in the National Cancer Plan, with regard to screening for cervical cancer, as the guideline aims to provide important information and support for planned organized screening for cervical cancer in Germany.

Methods With the financial support of German Cancer Aid, 21 professional societies developed evidence-based statements and recommendations (classified using the GRADE system) for the screening, management and treatment of precancerous conditions of the cervix. Two independent scientific institutes compiled systematic reviews for this guideline.

Recommendations The first part of this short summary presents the pathological basis and considers various questions related to screening for cervical cancer. As also reported in earlier reviews, the meta-analysis by Kleijnen Systematic Reviews showed that HPV-based screening offers better protection against invasive cervical cancer compared to cytology-based screening. The authors of this guideline therefore recommend – in accordance with the guideline of the Joint National Committee of Germany (Gemeinsamer Bundesauschuss, G-BA) – that women aged 35 and above should be examined at regular intervals (at least every 3 years) and undergo HPV-based screening. Co-testing can also be carried out. Women between the ages of 20 and 35 should have cytological screening every 2 years.